- Home
- LH vs DGX Comparison
LH vs DGX Comparison
Compare LH & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | DGX |
|---|---|---|
| Founded | 1971 | 1967 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7B | 23.1B |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | LH | DGX |
|---|---|---|
| Price | $255.63 | $188.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $311.33 | $214.38 |
| AVG Volume (30 Days) | 540.7K | ★ 891.6K |
| Earning Date | 04-30-2026 | 04-21-2026 |
| Dividend Yield | 1.11% | ★ 1.76% |
| EPS Growth | ★ 18.33 | 13.78 |
| EPS | ★ 10.46 | 2.24 |
| Revenue | ★ $13,951,700,000.00 | $11,035,000,000.00 |
| Revenue This Year | $8.26 | $7.53 |
| Revenue Next Year | $4.81 | $3.77 |
| P/E Ratio | ★ $24.80 | $87.10 |
| Revenue Growth | 7.25 | ★ 11.78 |
| 52 Week Low | $235.81 | $164.65 |
| 52 Week High | $293.72 | $213.50 |
Technical Indicators
Market Signals| Indicator | LH | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 38.39 |
| Support Level | $246.08 | $176.61 |
| Resistance Level | $275.06 | $193.04 |
| Average True Range (ATR) | 7.41 | 5.42 |
| MACD | -1.16 | -0.38 |
| Stochastic Oscillator | 11.91 | 6.15 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.